Drug intelligence / Profile preview

Oliclinomel

Development stage
Phase 4
Lead developer
Takeda
Modality
Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

OliClinomel is a ready-to-use, three-chamber parenteral nutrition (PN) emulsion designed for intravenous administration in adults and children over 2 years of age who cannot receive adequate nutrition orally or enterally. Each chamber contains a different component—an amino acid solution, a glucose solution with calcium, and an olive oil-based lipid emulsion (ClinOleic), which is composed of approximately 80% refined olive oil and 20% refined soya oil. The formulation provides essential amino acids for protein synthesis, glucose as an energy source, and lipids to supply essential fatty acids while aiming to reduce proinflammatory effects compared to pure soybean oil emulsions. OliClinomel supports nitrogen/energy balance, protein synthesis, immune function preservation, wound healing, and overall cellular activity in patients requiring PN[1][3][7]. It is manufactured by Baxter.

Brand names
Oliclinomel

Beyond the preview

Go deeper on Oliclinomel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oliclinomel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call